AbCellera Biologics Inc.: federal grants and contributions: 9 agreements; $417M value; 3 departments; 4 programs.
Assay record ASY-CA-12S0SQ1002 · Cite as: Assay Systems, “AbCellera Biologics Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/abcellera-biologics-inc/
This project builds capabilities for therapeutic antibody development, fortifies early-phase clinical research infrastructure, advances biotech IP for the health and economic benefit of Canadians and enables rapid response to future pandemics.
The project is in direct response to Canada's fight against COVID-19 and Canada's ability to respond to future pandemics. It will enable the rapid discovery of antibody therapies to treat and prevent COVID-19 and establish a Good Manufacturing Practice antibody production facility for Canada's long-term emergency preparedness.
Identify and develop antibody therapeutics for response and preparedness against COVID-19, and expand capacity for rapid development and delivery of antibody therapeutics.
Scale-up partnerships in therapeutic antibody discovery business
This project will develop, validate, and integrate new technologies to create a platform for the discovery of therapeutic antibodies against any target class, and with industry-leading speed, throughput, and efficiency.
All grants from Innovation, Science and Economic Development Canada
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.